



INNOVATIONS IN COVID-19

Bridging opportunities
at Oswaldo Cruz Institute

DEVELOPMENT OF ANTI-SARS-COV-2 ANTIBODY FRAGMENTS (COD. 2020.005)

COORDINATOR

Vinicius Cotta de Almeida

RESEARCH AREA

New Drugs

DEVELOPMENT STAGE

Level 1 - TRL - Basic principles observed and reported. MRL - Basic principles observed and reported.

PROPOSITION / APPLICATION

Application of molecular modelling tools for *in silico* alterations and tests to improve the interaction of the antibody with the target antigen. Successful *in silico* changes will be further tested *in vitro*.

INNOVATION

Use of *in silico* molecular modelling tools to generate antibody fragments with a potential neutralizing and protective effect against the infection of healthy cells by the new coronavirus, in relation to the antibodies already published.

OPPORTUNITY

Generation of new antibodies for preliminary tests on their behaviour and effectiveness, which can culminate in the production of a potential biotherapeutic product with a neutralizing / blocking function for SARS-CoV2 infection.

CONTACT

nit@ioc.fiocruz.br